BioNexus Gene Lab Corp. (BGLC)
NASDAQ: BGLC · Real-Time Price · USD
4.110
-0.220 (-5.08%)
At close: Dec 5, 2025, 4:00 PM EST
4.090
-0.020 (-0.49%)
After-hours: Dec 5, 2025, 7:52 PM EST
BioNexus Gene Lab Revenue
BioNexus Gene Lab had revenue of $2.54M in the quarter ending September 30, 2025, a decrease of -3.29%. This brings the company's revenue in the last twelve months to $9.47M, up 2.22% year-over-year. In the year 2024, BioNexus Gene Lab had annual revenue of $9.51M, down -2.66%.
Revenue (ttm)
$9.47M
Revenue Growth
+2.22%
P/S Ratio
0.78
Revenue / Employee
$315,500
Employees
30
Market Cap
7.38M
Revenue Chart
Revenue History
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Rio Tinto Group | 53.73B |
| BHP Group | 51.26B |
| CRH plc | 36.90B |
| Linde | 33.50B |
| Freeport-McMoRan | 26.00B |
| The Sherwin-Williams Company | 23.28B |
| Newmont | 21.50B |
| Ecolab | 15.89B |
BGLC News
- 3 days ago - BioNexus Gene Lab Corp. Completes Strategic Investment in Fidelion Diagnostics; Secures 15% Equity Stake in Global AI-Oncology Platform and Exclusive Southeast Asian Rights for VitaGuard™ - GlobeNewsWire
- 4 days ago - BioNexus Gene Lab Corp. (Nasdaq: BGLC) Secures $500 Million Equity Facility From ARC Group International to Support Expansion of Precision Diagnostics, CDMO Operations, and Therapeutic Commercialization - GlobeNewsWire
- 5 days ago - BioNexus Gene Lab Corp. (Nasdaq: BGLC) and Fidelion Diagnostics Execute Exclusive Southeast Asia License for VitaGuard™ MRD Platform as Part of Strategic Alliance with Tongshu Gene - GlobeNewsWire
- 24 days ago - BioNexus Gene Lab Corp. (Nasdaq: BGLC) Announces Strategic Agreements with Fidelion Diagnostics for Southeast Asia MRD Commercialization - GlobeNewsWire
- 26 days ago - BioNexus Gene Lab Corp. Files $100 Million Shelf Registration and Establishes $20 Million At-the-Market Program to Advance Strategic Growth Opportunities - GlobeNewsWire
- 6 weeks ago - BioNexus Gene Lab Corp Signs Strategic Partnership Term Sheet with BirchBioMed Inc. - GlobeNewsWire
- 4 months ago - BioNexus Gene Lab Corp. and Fidelion Diagnostics Announce Landmark Alliance—Touted as a new “DeepSeek Moment” in Precision Oncology - GlobeNewsWire
- 7 months ago - BioNexus Gene Lab Corp. Regains Nasdaq Compliance, Signaling Strategic Stability and Growth Readiness - GlobeNewsWire